Community pharmacies in resource-limited settings increasingly substitute antiretroviral regimens when viral load assay turnaround telemetry is delayed or unreliable, yet the resistance-safety consequences of such substitution rules are rarely quantified before deployment. the present analysis formulates regimen substitution as a distributionally robust optimisation problem over an ambiguity set of turnaround-time distributions, couples it to a stochastic within-host resistance model, and evaluates the resulting policies in a computed healthcare environment. The design is a before-after-control-impact (BACI) evaluation of the estimator that would be used to detect a policy's effect on resistance-safety outcomes, characterised under a declared variance structure with between-cluster SD = 6.0, residual SD = 4.5 and intraclass correlation = 0.64. Power was estimated across 2000 replications per design cell for cluster counts of 8, 16, 24 and 32 and effect sizes of 3, 5 and 8 percentage points.52 clusters are required to detect a 5-percentage-point effect at 80% power, that the minimum detectable effect falls steeply between 8 and 24 clusters, and that the BACI interaction estimator remains approximately nominal in coverage across the grid. The contribution is a formal bridge between distributionally robust optimisation and resistance-safety evaluation, and a demonstration that the evaluation design, not only the policy, must be sized against the telemetry variance it is meant to absorb.
No takes yet. Share an insight, caveat, or question.
Sithole et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: